GON Stock Chart & Stats
€1.42
-€0.03(-1.00%)
At close: 4:00 PM EST
€1.42
-€0.03(-1.00%)
Day’s Range― - ―
52-Week Range€0.92 - €1.63
Previous CloseN/A
Volume0.00
Average Volume (3M)550.00
Market Cap
€800.77M
Enterprise Value€934.92
Total Cash (Recent Filing)€314.29M
Total Debt (Recent Filing)€251.84M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume150
30 Day Avg. Volume550
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.51Price Target Upside147.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€205.73M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue RampA multi-year inflection in revenue and a 31% YoY Q1 increase indicate durable commercial adoption of RYTELO. Persistent top-line growth buttresses scale economies, funds continued R&D and commercialization, and improves the firm's ability to invest toward sustainable margins over 2–6 months.
Commercial Traction & Account ExpansionQuarterly demand growth and increasing prescribing accounts reflect expanding physician acceptance and deeper market penetration. These structural commercial gains support repeatable revenue streams, better forecasting, and higher long‑term uptake potential across treatment lines.
Balance Sheet CushionA meaningful equity cushion and manageable leverage provide financing flexibility while the company scales. This capital structure reduces immediate refinancing risk, enables continued commercial and clinical investment, and supports execution through upcoming milestones over the medium term.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flows signal the company is still consumption‑driven rather than self‑funding. Sustained cash burn requires either strong sustained revenue growth, further cost cuts, or external financing, all of which materially affect strategic flexibility over the coming months.
Widening Gross‑to‑Net PressureA structurally higher gross‑to‑net reduces realized revenue per unit and compresses margins even as volumes grow. Persistent 20%+ adjustments from payer mix and contracting materially erode cash conversion and make it harder to translate sales growth into durable profitability.
Clinical Outcome UncertaintyKey trial readouts are pivotal for label expansion, guideline uptake, and long‑term commercial trajectory. A negative or neutral interim could slow adoption and reduce upside across indications, altering revenue durability and the company’s ability to justify continued commercial investment.
Geron News
GON FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was €0.92 and its highest was €1.63 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is €800.77M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 06, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.018 by €0.009.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 641,521,000 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.018. Following the earnings report the stock price went up 7.491%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in DE:GON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.51 (147.41% Upside)
€3.51 (147.41% Upside)
Blogger Sentiment
Bullish
DE:GON Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial story: strong revenue growth (+31% YoY), expanding demand (+6% QoQ) and disciplined cost reductions position Geron to meet 2026 guidance. Important clinical and regulatory milestones (IMpactMF enrollment, NCCN order template inclusion, peer-reviewed publication) bolster the long-term value proposition. Key risks highlighted include widening gross-to-net pressure (21% vs 13% prior year), a meaningful quarter-over-quarter cash decline (~$60M) driven by one-time and supply investments, and unresolved European commercialization/pricing decisions. On balance, the favorable revenue trajectory, cost discipline and clinical progress outweigh the manageable near-term financial and market-access headwinds.View all DE:GON earnings summariesGON Stock 12 Month Forecast
Average Price Target
€3.51
▲(147.41% Upside)